Lincomycin shares many of the pharmacologic, toxicologic, and antibacterial properties of erythromycin. It offers few therapeutic advantages in comparison with erythromycin when the infecting microorganism is susceptible to both drugs. For the present lincomycin is clearly preferred only when the patient is intolerant to erythromycin, the infecting agent is insusceptible to erythromycin, or possibly when lincomycin-susceptible microorganisms are located within bone.
No takes yet. Share an insight, caveat, or question.
Eugene Sanders (1969) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: